Drugs / Paclitaxone
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06642545 Comparator | Feb 2025 → Oct 2026 expected | breast cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Paclitaxone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06642545 ↗ |
| Route | Intravenous | “125 mg/m2,intravenous infusion, D1-8, every 3 weeks” NCT06642545 ↗ |